The aluminum nanoparticle-encircled SQ-in-water emulsions (ANSWE) as a vaccine adjuvant-delivery system (VADS) for developing robust mucosal subunit vaccines
Source abstract
Abstract
The aluminum nanoparticle-encircled squalene (SQ)-in-water emulsions (ANSWE) were engineered as a VADS (vaccine adjuvant-delivery system) using a simple procedure for carrying antigens (Ag) to develop subunit vaccines. In vitro, due to possessing the synergistic adjuvanticity of both AN and SQ, ANSWE were efficiently taken up by APC (antigen-presenting cells) and triggered them to mature and make extra ROS (reactive oxygen species) and multiple cytokines, such as IL-12, IL-1β and IFN-β, which favor balanced Th1/Th2 immunoresponses. Within APC, ANSWE managed lysosome escape and consequently enhanced proteasome activities to facilitate Ag cross-presentation. Mice given twice ovalbumin-ANSWE via intrapulmonary vaccination (IPV) produced high levels of anti-Ag antibodies as well as cytotoxic T lymphocytes, which efficiently erased cells bearing cognate Ag. Thus, ANSWE as a potent VADS may be feasible for developing mucosal subunit vaccines that can elicit comprehensive immunity against infectious diseases, including especially the respiratory infections, and even aggressive cancers.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Animal Virus Infections Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (65)
Show source-provided references
1. Innovative translational platforms for rapid developing clinical vaccines against COVID-19 and other infectious disease10.1002/biot.202300658 ↗
2. From empiricism to rational design: a personal perspective of the evolution of vaccine development10.1038/nri3694 ↗
3. Vaccines: the fourth century10.1128/CVI.00290-09 ↗
4. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines10.1016/j.smim.2018.05.001 ↗
5. The next frontier for malaria vaccination10.1038/d41586-023-02048-z ↗
6. Vaccines and the future of human immunology10.1016/j.immuni.2010.09.014 ↗
7. Operation warp speed: implications for global vaccine security10.1016/S2214-109X(21)00140-6 ↗
8. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia10.1056/NEJMe2106315 ↗
9. Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity10.1021/acscentsci.1c00596 ↗
10. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-210.1016/j.cell.2020.10.043 ↗
11. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody respon- ses10.1038/s41467-020-20654-7 ↗
12. Nanoparticulate carriers used as vaccine adjuvant delivery systems10.1615/CritRevTherDrugCarrierSyst.2019027047 ↗
13. The immunobiology of aluminium adjuvants: how do they really work?10.1016/j.it.2009.12.009 ↗
14. Solution to vaccine mystery starts to crystallize
15. Gavin · 2006
16. Getting closer to the dirty little secret10.1016/j.immuni.2011.04.003 ↗
17. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants10.1038/nature06939 ↗
18. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity10.4049/jimmunol.0900164 ↗
19. Phospholipid bilayer-coated aluminum nanoparticles as an effective vaccine adjuvant-delivery system10.1021/acsami.5b00348 ↗
20. Nanoalum adjuvanted vaccines: small details make a big difference10.1016/j.smim.2021.101544 ↗
21. Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology10.1038/s41541-018-0094-0 ↗
22. Aluminum (oxy)hydroxide Nanosticks synthesized in Bicontinuous reverse microemulsion have potent vaccine adjuvant activity
23. Covering aluminum oxide nanoparticles with biocompatible materials to efficiently deliver subunit vaccines10.3390/vaccines7020052 ↗
24. From sharks to yeasts: squalene in the development of vaccine adjuvants10.3390/ph15030265 ↗
25. “World in motion” – emulsion adjuvants rising to meet the pandemic challenges10.1038/s41541-021-00418-0 ↗
26. Type I interferons in infectious disease10.1038/nri3787 ↗
27. Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines10.1016/j.vaccine.2020.12.051 ↗
28. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action10.4049/jimmunol.1101764 ↗
29. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population10.1128/JVI.01776-13 ↗
30. Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza10.1016/j.isci.2021.103131 ↗
31. Constructing the cGAMP-aluminum nanoparticles as a vaccine adjuvant-delivery system (VADS) for developing the efficient pulmonary COVID-19 subunit vaccines
32. J. Wang, P. Li, Y. Yu, Y. Fu, H. Jiang, M. Lu, Z. Sun, S. Jiang, L. Lu, M.X. Wu, Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity, Science (1979) 367 (2020). doi:https://doi.org/10.1126/science.aau0810.10.1126/science.aau0810 ↗
33. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization10.1016/j.jconrel.2019.04.025 ↗
34. Smart combination of aluminum hydroxide and MF59 to induce strong cellular immune responses10.1016/j.jconrel.2022.07.032 ↗
35. Optimising the oil phases of aluminium hydrogel-stabilised emulsions for stable, safe and efficient vaccine adjuvant10.1007/s11705-021-2123-1 ↗
36. Augmenting vaccine efficacy: tailored immune strategy with alum-stabilized Pickering emulsion10.1016/j.vaccine.2024.05.070 ↗
37. Bradford assay for determining protein concentration10.1101/pdb.prot102269 ↗
38. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow10.1016/S0022-1759(98)00204-X ↗
39. Combining different types of multi- functional liposomes loaded with ammonium bicarbonate to fabricate microneedle arrays as a vaginal mucosal vaccine adjuvant-dual delivery system (VADDS)10.1016/j.jconrel.2016.12.009 ↗
40. Membrane fusion mediated intra- cellular delivery of lipid bilayer coated mesoporous silica nanoparticles10.1002/adhm.201700759 ↗
41. The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century10.1080/21645515.2023.2189885 ↗
42. Emerging concepts in the science of vaccine adjuvants10.1038/s41573-021-00163-y ↗
43. Immunoproteasomes: structure, function, and antigen presentation10.1016/B978-0-12-397863-9.00003-1 ↗
44. Proteasomes: isolation and activity assays
45. Using procedure of emulsification-lyophilization to form lipid A-incorporating cochleates as an effective oral mucosal vaccine adjuvant-delivery system (VADS)10.1016/j.ijpharm.2014.04.002 ↗
46. Perforin and granzymes: function, dysfunction and human pathology10.1038/nri3839 ↗
47. In vivo assessment of specific cytotoxic T lymphocyte killing10.1016/j.ymeth.2013.02.007 ↗
48. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response10.1016/j.vaccine.2007.06.049 ↗
49. Mechanisms of antigen adsorption onto an aluminum-hydroxide adjuvant evaluated by high-throughput screening10.1016/j.xphs.2016.03.032 ↗
50. Surface phosphophilicity of aluminum-containing adjuvants probed by their efficiency for catalyzing the P-O bond cleavage with chromogenic and fluorogenic substrates10.1006/abio.2001.5175 ↗
51. Caveolae: from cell biology to animal physiology10.1124/pr.54.3.431 ↗
52. The roles of CD28 and CD40 ligand in T cell activation and tolerance10.4049/jimmunol.164.9.4465 ↗
53. Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway10.7554/eLife.52687 ↗
54. The mechanism of action of MF59 – an innately attractive adjuvant formulation10.1016/j.vaccine.2011.09.061 ↗
55. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology10.1038/s41580-022-00456-z ↗
56. The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles
57. The basics of thiols and cysteines in redox biology and chemistry10.1016/j.freeradbiomed.2014.11.013 ↗
58. Mitochondrial iron–sulfur clusters: structure, function, and an emerging role in vascular biology: mitochondrial Fe-S clusters – a review10.1016/j.redox.2021.102164 ↗
59. Reactive oxygen species in the immune system10.3109/08830185.2012.755176 ↗
60. Mitochondrial reactive oxygen species drive proinflammatory cytokine production10.1084/jem.20110367 ↗
61. The NLRP3 inflammasome: molecular activation and regulation to therapeutics10.1038/s41577-019-0165-0 ↗
62. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome10.1073/pnas.0804897106 ↗
63. Cross-presentation by dendritic cells10.1038/nri3254 ↗
64. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing10.1038/ni.3558 ↗
65. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling10.1038/nature07317 ↗